Moderna's stock has risen after the company announced that the Covid vaccination has shown promise in a lab environment against a variety of variations, including delta.
Moderna's stock has risen after the company announced that the Covid vaccination has shown promise in a lab environment against a variety of variations, including delta. Moderna announced on Tuesday that its Covid-19 vaccine showed promise against coronavirus variants in a lab setting, including the highly contagious delta form initially found in India. According to Moderna, the two-dose mRNA vaccination elicited neutralizing antibodies against delta, beta, and eta, variations originally discovered in South Africa and Nigeria, respectively. The findings were based on the blood serum of eight participants one week after receiving the second dosage of the vaccine, according to the company. The information hasn't been peer-reviewed yet. While the results are encouraging, they may not accurately reflect how the vaccinations operate in real-world circumstances against the variations. It also comes on the same day that Moderna announced that their vaccine has been approved for us...